title: Extracorporeal photopheresis for the treatment of cutaneous T-cell lymphoma.
abstract: BACKGROUND
  Many regimens are used for cutaneous T-cell lymphoma (CTCL), but with advanced disease response rates and patient survival are not adequate with any current therapy. Recently extracorporeal photochemotherapy (ECP) was proposed as an alternative therapy.
  
  
  OBJECTIVE
  Our purpose is to present the results of ECP in patients with CTCL refractory to other treatments.
  
  
  METHODS
  Patients with CTCL received ECP at 3- to 5-week intervals for at least 6 months. All patients except one were in stage T2 (patch/plaque) or higher. Eight patients had extracutaneous disease involving lymph nodes (six patients), bone marrow (five), or Sézary cells (six). The interval between initial symptoms and diagnosis was 5.9 +/- 1.9 years (mean +/- standard error of the mean) and the interval between diagnosis and ECP was 2.2 +/- 0.4 years.
  
  
  RESULTS
  A complete response (disappearance of all lesions) was obtained in five patients (25%) and a partial response (disappearance of at least 50% of lesions) in six patients (30%). Four patients (20%) showed stabilization of their disease and five progressed (25%). The only variable that predicted responders versus nonresponders was the number of ECP sessions (p < 0.05 by multivariate logistic regression). In contrast, no separate beneficial effect of adjunctive chemotherapy (p > 0.5) or electron beam therapy (p > 0.1) was found.
  
  
  CONCLUSIONS
  Long-term ECP may be an effective alternative treatment for CTCL refractory to other therapies and is likely to be even more useful when combined with other modalities.
authors.affiliation: Division of Dermatology, Vanderbilt University, Nashville, TN 37232.
authors.forename: J
authors.initials: J
authors.lastname: Zic
authors.forename: C
authors.initials: C
authors.lastname: Arzubiaga
authors.forename: K E
authors.initials: KE
authors.lastname: Salhany
authors.forename: R A
authors.initials: RA
authors.lastname: Parker
authors.forename: D
authors.initials: D
authors.lastname: Wilson
authors.forename: G P
authors.initials: GP
authors.lastname: Stricklin
authors.forename: J
authors.initials: J
authors.lastname: Greer
authors.forename: L E
authors.initials: LE
authors.lastname: King
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003131:Combined Modality Therapy; D005112:Extracorporeal Circulation; D005260:Female; D006801:Humans; D016410:Lymphoma, T-Cell, Cutaneous / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008730:Methoxsalen / Q000627:therapeutic use; D008875:Middle Aged; D009367:Neoplasm Staging; D010778:Photochemotherapy / Q000009:adverse effects / Q000379:methods*; D012074:Remission Induction; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology
chemical_list: D008730:Methoxsalen